Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neuroblastoma

ClinicalTrials.gov lists 725 trials for Neuroblastoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 83.

MeSH D009447 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 232 Phase 1/2 Phase 1/2 70 Phase 2 Phase 2 194 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 47 Phase 4 Phase 4 5 Not applicable Not applicable 61 Observational Observational 98 Phase 1 Phase 1 232 Phase 1/2 Phase 1/2 70 Phase 2 Phase 2 194 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 47 Phase 4 Phase 4 5 Not applicable Not applicable 61 Observational Observational 98

Trials per phase (log scale)

1 more section with rows

651 of the 725 trials are tagged with Neuroblastoma itself; the rest are tagged with a narrower condition beneath it.

Get the Neuroblastoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neuroblastoma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 40

1990: 2 trials (Not applicable 1, Phase 3 1) 1991: 2 trials (Observational 1, Phase 1 1) 1992: 4 trials (Observational 1, Not applicable 1, Phase 2 2) 1993: 2 trials (Phase 2/3 1, Phase 2 1) 1994: 2 trials (Phase 2 2) 1995: 7 trials (Observational 1, Phase 3 1, Phase 2 3, Phase 1 2) 1996: 8 trials (Phase 2 3, Phase 1 5) 1997: 16 trials (Not applicable 1, Phase 2 6, Phase 1/2 2, Phase 1 7) 1998: 16 trials (Not applicable 1, Phase 3 2, Phase 2 7, Phase 1/2 1, Phase 1 5) 1999: 17 trials (Phase 3 3, Phase 2 11, Phase 1 3) 2000: 20 trials (Observational 2, Phase 3 3, Phase 2 4, Phase 1/2 3, Phase 1 8) 2001: 23 trials (Observational 1, Not applicable 2, Phase 3 4, Phase 2 2, Phase 1/2 1, Phase 1 13) 2002: 13 trials (Not applicable 2, Phase 3 2, Phase 2 3, Phase 1 6) 2003: 19 trials (Observational 1, Not applicable 4, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 5) 2004: 21 trials (Observational 1, Not applicable 4, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 9) 2005: 27 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2 9, Phase 1/2 1, Phase 1 12) 2006: 23 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 7, Phase 1 7) 2007: 33 trials (Observational 7, Not applicable 2, Phase 3 4, Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 11) 2008: 40 trials (Observational 13, Not applicable 4, Phase 3 2, Phase 2 12, Phase 1/2 3, Phase 1 6) 2009: 22 trials (Observational 5, Not applicable 1, Phase 2 6, Phase 1/2 3, Phase 1 7) 2010: 28 trials (Observational 7, Not applicable 1, Phase 3 2, Phase 2 8, Phase 1/2 1, Phase 1 9) 2011: 34 trials (Observational 9, Not applicable 4, Phase 3 1, Phase 2 5, Phase 1/2 4, Phase 1 11) 2012: 17 trials (Observational 5, Not applicable 2, Phase 1/2 5, Phase 1 5) 2013: 28 trials (Observational 3, Not applicable 3, Phase 3 2, Phase 2 8, Phase 1/2 2, Phase 1 10) 2014: 24 trials (Observational 1, Not applicable 4, Phase 3 1, Phase 2 4, Phase 1/2 5, Phase 1 9) 2015: 18 trials (Observational 1, Phase 2 9, Phase 1/2 2, Phase 1 6) 2016: 26 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 2 5, Phase 1/2 1, Phase 1 12) 2017: 22 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 12, Phase 1/2 1, Phase 1 5) 2018: 20 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 5) 2019: 19 trials (Observational 3, Phase 4 2, Phase 2 4, Phase 1/2 1, Phase 1 9) 2020: 17 trials (Not applicable 2, Phase 2 6, Phase 1/2 3, Phase 1 6) 2021: 23 trials (Observational 3, Phase 3 2, Phase 2 5, Phase 1/2 4, Phase 1 9) 2022: 17 trials (Observational 4, Not applicable 1, Phase 2 7, Phase 1/2 2, Phase 1 3) 2023: 18 trials (Observational 2, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 4) 2024: 29 trials (Observational 5, Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 2 8, Phase 1/2 5, Phase 1 7) 2025: 25 trials (Observational 7, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1/2 5, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 20
2025 25
2024 29
2023 18
2022 17
2021 23
2020 17
2019 19
2018 20
2017 22

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 25 trials starting in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 67 trials still running at the 2026-10-09 snapshot; registered median of 53 months across 450 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neuroblastoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 232
Phase 1/2 70
Phase 2 194
Phase 2/3 5
Phase 3 47
Phase 4 5
Not applicable 61
Observational 98
Expanded access 13

How many Neuroblastoma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 12
Recruiting 99
Enrolling by invitation 4
Active, not recruiting 55
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neuroblastoma trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 83
Children's Oncology Group 58

Which drugs are being tested for Neuroblastoma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 96
Melphalan 42
TOPOTECAN 39
Irinotecan 34

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Etoposid 64
or carboplatin 54
Vincristina 51
Filgrastime (G-CSF) 49
Doxorubicine 45

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neuroblastoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hypotension 314 31
Fever 312 25
Neutrophil count decreased 218 19
Lymphocyte count decreased 182 15
Febrile neutropenia 178 40

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neuroblastoma? (476)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
[<sup>18</sup>F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET. European journal of nuclear medicine and molecular imaging 2026 Yes
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nature medicine 2025 Yes
Dilemma on Pancreatic Uncinate Process Uptake on Ga68-DOTA Peptide PET/CT in Pediatric Neuroblastoma: Physiologic or Metastases? Current radiopharmaceuticals 2025 Yes
Radiation Exposure to Patients and Others During Therapy for Pediatric Neuroblastoma With Lu-177-DOTATATE. Clinical nuclear medicine 2025 Yes
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes

Showing 5 of 476 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (15)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Neuroblastoma Prevalence at birth 1-9 / 100 000 United States US Exact
Neuroblastoma Prevalence at birth 1-9 / 100 000 United States US Unspecified
Neuroblastoma Prevalence at birth 1-9 / 100 000 United States US Exact
Neuroblastoma Prevalence at birth 1-5 / 10 000 Germany Not stated Unspecified
Neuroblastoma Point prevalence 1-5 / 10 000 Europe Not stated Exact

Showing 5 of 15 prevalence observations.

Start your 14-day trial Email me all 15 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Neuroblastoma 635 Exact Orphanet Rare Disease Ontology (ORDO)
Neuroblastoma 635 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages